Glucosio Monico

Glucosio Monico is an intravenous solution that contains glucose monohydrate as its sole active ingredient. Marketed in the European Union and supplied by prescription only, the product provides a carbohydrate source for parenteral nutrition and rapid correction of low blood glucose. It is presented as a sterile solution for intravenous infusion, with no specified strength disclosed in the label and is intended for use under medical supervision.

Glucosio Monico is indicated for clinical situations where an immediate source of glucose is required.

- Treatment of hypoglycemia in patients unable to take oral glucose. - Provision of carbohydrate calories as part of total parenteral nutrition (TPN). - Support of fluid and electrolyte balance during peri‑operative care. - Replacement of glucose losses in patients with prolonged fasting or severe catabolism. - Adjunctive therapy for patients receiving insulin infusions to prevent rapid glucose declines.

Adverse reactions to Glucosio Monico are generally related to the intravenous administration of a glucose solution.

Common: - Mild rise in plasma glucose levels when administered in larger volumes than required. - Local irritation, redness, or pain at the catheter insertion site. - Nausea or brief vomiting if the infusion rate is rapid. - Transient headache or dizziness during or shortly after infusion.

Serious: - Marked hyperglycemia that may progress to osmotic diuresis. - Allergic or anaphylactic response to the solution constituents. - Fluid overload with risk of pulmonary edema, especially in patients with cardiac dysfunction. - Significant electrolyte imbalance such as severe hypokalemia or hyponatremia.

When prescribing Glucosio Monico, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline blood glucose and adjust infusion rate to avoid hyperglycemia. - Monitor electrolyte levels, particularly sodium and potassium, during therapy. - Use caution in patients with renal or hepatic impairment due to altered glucose metabolism. - Evaluate cardiac function before infusion in individuals at risk for fluid overload. - Avoid rapid infusion in neonates and infants to prevent metabolic disturbances. - Document any history of allergy to carbohydrate solutions.

Glucosio Monico may interact with other agents that affect glucose homeostasis or fluid balance.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring, which can precipitate severe hypoglycemia. - Co‑administration with other hypertonic glucose solutions, which may cause excessive hyperglycemia.

Use with caution: - Diuretics that alter electrolyte status, requiring close monitoring of sodium and potassium. - Corticosteroids that increase glucose production, potentially enhancing hyperglycemic risk. - Cardiac medications (e.g., digoxin) in patients prone to fluid overload, necessitating careful volume assessment.